Table 1 Characteristics of eligible studies for survival analysis
Author | Year | Country | Sample size | Percent of IDC (%) | Cut-offa | Follow-up | Protein | Survival outcome | HR data | Survival analysis | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|
Talvensaari-Mattila [51] | 1998 | Finland | 169 | 82 | P > 0% | 92 months | MMP2 | OS | Rep | U | 8 |
Talvensaari-Mattila [50] | 1999 | Finland | 108 | 96 | P > 0% | 2 years | MMP2 | RFS | Est | U | 8 |
Talvensaari-Mattila [49] | 2001 | Finland | 100 | 79 | P > 0% | 44 months | MMP2 | OS, RFS | Est | U | 7 |
Scorilas | 2011 | Greece | 210 | 75 | HSCORE> 175 | 62 months | MMP9 | OS, RFS | Rep | U, M | 7 |
Djonov [48] | 2002 | Switzerland | 75 | 61 | SI ≥ 1 | NR | MMP2 | OS, DFS | Rep | M | 6 |
Hirvonen [47] | 2003 | Finland | 137 | NR | P > 0% | 10 years | MMP2 | RFS | Est | U | 6 |
Fan [45] | 2003 | China | 66 | 86 | SI ≥ 1 | 30.5 months | MMP2, MMP9 | OS | Rep | M | 6 |
Talvensaari-Mattila [44] | 2003 | Finland | 453 | 75 | P > 0% | 60–150 months | MMP2 | OS | Rep | M | 8 |
Li [19] | 2004 | China | 270 | 90 | P > 0% | 61 months | MMP2, MMP9 | OS, RFS | Rep | U, M | 6 |
Pellikainen [58] | 2004 | Finland | 415 | 64 | P > 85%b | 55 months | MMP9 | RFS | Rep | M | 7 |
Rahko [23] | 2004 | Finland | 168 | 75 | P > 1% | 7–111 months | MMP9 | OS, DFS | Rep | U | 7 |
Ban [52] | 2004 | China | 60 | 100 | SI ≥ 3 | > 5 years | MMP2 | OS | Est | U | 7 |
Zhou [42] | 2005 | China | 112 | 84 | P > 5% | 48 months | MMP2 | OS | Rep | M | 7 |
Zhang [38] | 2008 | China | 263 | 100 | SI ≥ 6 | 92.1 months | MMP2, MMP9 | OS | Rep | U | 6 |
Zhao [53] | 2008 | China | 71 | 93 | P > 10% | 54.94 months | MMP9 | OS | Est | U | 6 |
Sullu [22] | 2011 | Turkey | 140 | 100 | SI ≥ 5 | 63.2 months | MMP9 | OS, DFS | Est | U | 8 |
Ranogajec [37] | 2012 | Croatia | 138 | 59 | SI ≥ 2 | 5 years | MMP2 | OS | Est | U | 7 |
Fernandez-Guinea [21] | 2013 | Spain | 97 | 100 | SI | > 5 years | MMP2, MMP9 | RFS | Rep | U, M | 6 |
Zhao [18] | 2013 | China | 127 | NR | SI ≥ 6 | NR | MMP9 | OS | Rep | M | 6 |
Liu [17] | 2013 | China | 189 | 89 | P > 10% | NR | MMP9 | OS | Rep | U, M | 8 |
Zeng [36] | 2013 | China | 253 | NR | P > 20% | 15 years | MMP9 | OS, DFS | Rep | U, M | 8 |
Merdad [20] | 2014 | Saudi Arabia | 45 | 84 | SI ≥ 2 | 52.1 months | MMP9 | OS | Rep | U | 7 |
Puzovic [35] | 2014 | Croatia | 121 | 100 | SI | 80.6 months | MMP2, MMP9 | OS, DFS | Rep | U | 7 |
Min [32] | 2014 | Korea | 177 | 100 | SI ≥ 1, SI ≥ 5 | NR | MMP2, MMP9 | OS | Rep | M | 7 |
Yousef [30] | 2014 | Canada | 300 | NR | SI ≥ 5 | NR | MMP9 | RFS | Est | U | 6 |
Bottino [59] | 2014 | Brazil | 60 | 1 | MOD> 191 | NR | MMP9 | OS | Rep | U | 7 |
Huang [55] | 2014 | China | 147 | 86 | P > 10% | 45.6 months | MMP9 | OS, DFS | Rep | U, M | 6 |
Ramos [29] | 2016 | Brazil | 44 | 77 | P > 10% | NR | MMP2 | OS, DFS | Est | U | 7 |
Li [16] | 2017 | China | 80 | NR | P > 25% | NR | MMP2, MMP9 | OS | Est | U | 7 |
Yang [28] | 2018 | Korea | 173 | 100 | SI ≥ 2 | NR | MMP9 | OS, DFS | Rep | U, M | 8 |
Zhang [56] | 2019 | China | 127 | NR | SI ≥ 6 | NR | MMP9 | OS | Rep | M | 7 |